Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510582 · ClinicalTrials.gov registry record · Phase 1
Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection
A Phase 1 study of Chronic Subdural Hematoma, sponsored by The Cooper Health System.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT06510582 is a Phase 1 study of Chronic Subdural Hematoma that is actively recruiting participants, run by The Cooper Health System. The registered enrollment target is 140 participants, below the 1,407-participant average among 4 other Chronic Subdural Hematoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06510582, a Phase 1 study of Chronic Subdural Hematoma, is actively recruiting participants, sponsored by The Cooper Health System.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH). The main questions it aims to answer are: * Is bevacizumab infusion safe in cSDH patients? * Is bevacizumab infusion effective in treating cSDH?
Conditions Studied
Interventions
- DRUG Bevacizumab 2 mg/kg
- DRUG Bevacizumab 4 mg/kg
Study Locations (1)
New Jersey
- Cooper University Health Care - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-06-17 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06510582
The ClinicalTrials.gov registry entry for NCT06510582 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,407-participant average among 4 other Chronic Subdural Hematoma trials with a reported enrollment target (90% lower). The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Subdural Hematoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab 2 mg/kg is the first listed.
NCT06510582 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06510582 about?
NCT06510582 is a clinical study titled "Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection". The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH). The main questions it aims to answer are: * Is bevacizumab infusion safe in cSDH patients? * Is bevacizumab infusion effective in treat...
What is the current status of trial NCT06510582?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2024-06-17. Estimated completion is 2028-06.
What conditions does trial NCT06510582 study?
This clinical trial studies the following conditions: Chronic Subdural Hematoma.
What interventions are being tested in trial NCT06510582?
The interventions under investigation include: Bevacizumab 2 mg/kg (DRUG), Bevacizumab 4 mg/kg (DRUG).
Who is sponsoring clinical trial NCT06510582?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06510582 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Subdural Hematoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)
RECRUITING
-
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
RECRUITING · NA
-
Microfabricated Microcatheter Advantages in Middle Meningeal Artery Embolization: an Early Experience at a Single Center
RECRUITING
-
Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.